Health Care Related Organization

CDC highlights strong effectiveness of 2024–2025 COVID-19 shots in kids while FDA reviews reports of alleged post-vaccination deaths

3 days ago talkbio0Tagged alleged deaths, Centers for Disease Control and Prevention (U.S.), Child, COVID19 (disease), Effectiveness, Emergency department patient visit, Pediatrics, safety review, United States Food and Drug Administration, urgent care visits, Vaccines, VAERS

CDC; FDA; COVID-19 vaccine; children; pediatrics; vaccine effectiveness; emergency department visits; urgent care visits; safety review; alleged deaths; VAERS

Pfizer, Geron Downsize to Streamline Costs

3 days ago talkbio0Tagged commercial strategy, cost-cutting, Geron, Pfizer, Rytelo, Staff, Switzerland

Pfizer layoffs Switzerland; Geron layoffs one-third staff; cost-cutting; restructuring plan; Rytelo commercial strategy; Pfizer cost realignment; biopharma layoffs 2025

Pfizer’s Tukysa Shows Strong PFS Benefit in First-Line HER2+ Breast Cancer Maintenance at SABCS 2025, Sparking Debate with Enhertu

3 days ago talkbio0Tagged Enhertu, first-line maintenance, HER2-positive carcinoma of breast, HER2CLIMB-05, Pfizer, Progression-Free Survival, SABCS, Tukysa

Tukysa; Pfizer; HER2-positive breast cancer; SABCS 2025; HER2CLIMB-05; progression-free survival; Enhertu; first-line maintenance

Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial

4 days ago talkbio0Tagged Adjuvant Therapy, Disease-Free Survival, ER-positive, giredestrant, HER2-negative, hormone receptor-positive, Hormone Therapy, Malignant neoplasm of breast, Oral SERD, phase III lidERA trial, Recurrence Risk, Roche (company), San Antonio Breast Cancer Symposium

Roche; giredestrant; breast cancer; hormone receptor-positive; ER-positive; HER2-negative; oral SERD; endocrine therapy; adjuvant therapy; recurrence risk; phase III lidERA trial; disease-free survival; San Antonio Breast Cancer Symposium

Spotlight On: It’s Raining AI Devices as Regulatory Storm Reshapes Digital Health

4 days ago talkbio0Tagged 2025, Accountability, AI-enabled, clinical oversight, digital health regulation, digital mental health devices, draft guidance, EU, EU AI Act health, Generative AI, Health care facility, Medical Devices, Regulation, Software as a Medical Device, United States Food and Drug Administration

AI-enabled medical devices; digital health regulation 2025; FDA AI draft guidance; EU AI Act health; generative AI in healthcare; SaMD regulation; clinical oversight of AI; AI accountability in healthcare; digital mental health devices

Recent advances in AI for antimicrobial resistance (AMR) prevention and control

4 days ago talkbio0Tagged AI antibiotic discovery, Antibiotics, Antimicrobial Resistance, Diagnostics, Generative AI, GPR182 gene, Health care facility, Machine Learning, Phage Therapy, Stewardship, surveillance aspects

antimicrobial resistance; AI in healthcare; machine learning; antibiotic stewardship; AI antibiotic discovery; phage therapy; rapid diagnostics; AMR surveillance; generative AI

Concr Adds Former AstraZeneca and Cancer Research Institute Executives to Advisory Board

4 days ago talkbio0Tagged Advisory Board, AstraZeneca, Biological Science Disciplines, cancer drug development, Cancer Research Institute, DDX11-AS1 gene, executive appointments, Neoplasms, strategic advisory

Concr; AstraZeneca; Cancer Research Institute; advisory board; biotech; oncology; executive appointments; life sciences; strategic advisory; cancer drug development

FDA reviews safety of approved RSV antibodies for infants

4 days ago talkbio0Tagged AstraZeneca, Beyfortus, Infant, Merck, nirsevimab, palivizumab, Respiratory syncytial virus, RSV antibodies, safety review, sanofi, United States Food and Drug Administration

FDA; RSV; nirsevimab; Beyfortus; palivizumab; RSV antibodies; infant safety review; Sanofi; AstraZeneca; Merck; respiratory syncytial virus

UK cuts 2026 new-medicine rebate rate to 14.5% under VPAG

5 days ago talkbio0Tagged branded medicines, clawback rate, Drug Industry, drug price, Growth, Nance-Horan syndrome, rebate rate, United Kingdom, valproic acid glucuronide, Voluntary Scheme

United Kingdom; VPAG; Voluntary Scheme for Branded Medicines Pricing Access and Growth; rebate rate; clawback rate; new medicines; NHS; drug pricing; pharmaceutical industry; 2026

FDA Broadens COVID-19 Vaccine Safety Probe to Adults Under New Health Leadership

5 days ago talkbio0Tagged Adult, COVID19 (disease), Moderna, Myocarditis, Pfizer, public trust, safety review, United States Food and Drug Administration, vaccine deaths, Vaccines

FDA; COVID-19 vaccines; safety review; adults; Robert F. Kennedy Jr.; vaccine deaths; public trust; Pfizer; Moderna; myocarditis